Table 1.
Patient | Age | Serum PSA (ng/ml) | Index lesion | 18F-DCFBC visual analysis (lesion visibility) | SUVmax at 1hr p.i. |
---|---|---|---|---|---|
1 | 73 | 38.64 | Gleason 4+5 | positive | 16.3 |
2 | 67 | 46.47 | Gleason 4+5 | positive | 4.6 |
3 | 51 | 4.36 | Gleason 4+3 | positive | 3.1 |
4 | 53 | 49.92 | Gleason 4+5 | positive | 5.9 |
5 | 59 | 9.61 | Gleason 3+4 | negative | 2.1 |
6 | 66 | 216.4 | Gleason 4+4 | positive | 6.3 |
7 | 69 | 47.03 | Gleason 4+5 | positive | 2.7 |
8 | 55 | 16.53 | Gleason 3+4 | negative | 2.3 |
9 | 66 | 8.71 | Gleason 3+4 | positive | 3.6 |
10 | 72 | 26.02 | Gleason 4+4 | negative | 2.3 |
11 | 74 | 3.24 | Gleason 3+4 | equivocal | 3.0 |
12 | 53 | 3.26 | Gleason 4+3 (with ductal features) | equivocal | 3.1 |
13 | 54 | 10.85 | Gleason 4+4 | positive | 4.2 |